Pasithea Therapeutics (KTTA) EBT Margin (2022)
Pasithea Therapeutics (KTTA) posted EBT Margin of 2126.06% for Q4 2022, down 1.34% sequentially from 2097.88% in Q3 2022.
Pasithea Therapeutics (KTTA) EBT Margin (2022) Analysis & Trends
Pasithea Therapeutics has reported EBT Margin for 1 years, with the latest figure at 2126.06% in Q4 2022.
- Quarterly EBT Margin changed N/A year-over-year to 2126.06% in Q4 2022, while the trailing twelve-month figure through Dec 2022 was 2864.29% (changed N/A YoY) and the FY2022 annual result came in at 2864.29%, up 1156621.0% from the prior year.
- EBT Margin slipped to 2126.06% in Q4 2022 per KTTA's latest filing, from 2097.88% in the prior quarter.
- Over five years, EBT Margin peaked at 2097.88% in Q3 2022 and troughed at 19574.36% in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 35.71% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -528.97% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 18.33% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 13.77% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -25.06% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -2.67% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 12.09% |
| 10 | Pasithea Therapeutics | 16.97 Mn | 16.97 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | -2,126.06% |
| Sep 30, 2022 | -2,097.88% |
| Jun 30, 2022 | -19,574.36% |
| Mar 31, 2022 | -11,526.14% |